Therapie des unbehandelten lokal fortgeschrittenen oder metastasierten Nierenzellkarzinoms
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 214) – AN 36/15 der AUO